Funder: National Institutes of Health

Due Dates: June 16, 2025 (New) | July 16, 2025 (Renewal/Resubmission/Revision) | September 7, 2025 (AIDS) | October 16, 2025 (New) | November 16, 2025 (Renewal/Resubmission/Revision) | January 7, 2026 (AIDS) | ...through September 7, 2028

Funding Amounts: Up to $275,000 direct costs over 2 years; no more than $200,000 in any single year; project period max 2 years.

Summary: Supports early-stage, innovative research to advance cancer control through behavioral, screening, etiologic, and population-based studies.

Key Information: R21 mechanism; clinical trials are optional; preliminary data not required; foreign organizations eligible.